Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (2115)	7/14/1999 12:52:00 AM
From: Kevin Podsiadlik	Respond to of 10293

wasn't that touted this evening by Ron Insana Doubtful. "Tout" and "Ron Insana" are not compatible terms.

To: Mike M who wrote (2115)	7/14/1999 1:55:00 AM
From: mchip	Read Replies (2) \| Respond to of 10293

Putting the merits or not of VPHM aside, don't you see VPHM as a competitor to GUMM? and with actual FDA trials. What were you trying to point out Mike?

To: Mike M who wrote (2115)	7/14/1999 9:44:00 AM
From: Hank	Respond to of 10293

Yes, that's one and the same. It's hardly a cure for the common cold though. That's why it's only indications are for those who suffer severe symptoms like viral meningitis. In spite of the hype currently surrounding it, you're not likely to see anybody taking this stuff for your average run of the mill cold. The hype machine may push this baby back over 20. There is also a fairly large short interest (333,000 as of Jun 15th, so a short squeeze is very possible. If it gets back over 20, short the hell out of it. Pleconaril will NEVER be a billion dollar drug.